Imugene Secures $5.8 Million R&D Tax Refund to Advance Cancer Therapies

Imugene ( (AU:IMU) ) has issued an announcement.

Imugene Limited has received a $5.8 million R&D tax refund from the Australian Government, which will support the further development of its immuno-oncology pipeline. This financial boost is expected to enhance the company’s clinical efforts and strengthen its position in the rapidly growing global market for cancer treatments, benefiting stakeholders and potentially advancing the effectiveness of cancer therapies.

The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumors. The company’s pipeline includes a variety of therapies, such as an off-the-shelf cell therapy CAR T drug targeting blood cancers, multiple B-cell vaccine candidates, and an oncolytic virotherapy aimed at treating various cancers. Imugene collaborates with international cancer experts and aims to transform cancer treatment, supported by clinical evidence and research.

YTD Price Performance: -65.42%

Average Trading Volume: 575,177

Technical Sentiment Signal: Sell

Current Market Cap: A$3.55B

For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.